Lupin Limited entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited to expand access to innovative Semaglutide injection (15 mg/3 ml) in India. The therapy will be offered through a patient-friendly reusable pen device, improving convenience and adherence. The strategic collaboration combines Lupin’s strong domestic market presence with Zydus’ advanced research and development capabilities. Together, both companies aim to accelerate access to next-generation therapies for metabolic disorders, particularly diabetes and obesity.
Key Highlights of the Licensing Agreement
Under the terms of the agreement, Lupin will receive semi-exclusive rights to co-market Zydus’ semaglutide injection in India. The product will be sold under the brand names Semanext® and Livarise® (Lupin), while Zydus will continue marketing it under SEMAGLYN™, MASHEMA™, and ALTERME™. Additionally, Lupin will pay upfront licensing fees along with milestone-based payments tied to pre-defined commercial and regulatory achievements. This structure ensures a performance-driven partnership aligned with long-term growth.
Strengthening Diabetes and Cardio-Metabolic Portfolio
Nilesh Gupta highlighted its strategic importance. He emphasized that the collaboration reinforces Lupin’s commitment to advancing treatment options for cardio-metabolic diseases. He further noted that GLP-1 therapies are transforming global treatment standards. Therefore, this partnership not only strengthens Lupin’s diabetes portfolio but also helps address critical unmet patient needs across India.
Focus on Innovation and Patient Convenience
Sharing his perspective, Sharvil Patel underscored the company’s patient-centric approach. He stated that Zydus continues to focus on life-changing innovations that improve patient outcomes and quality of life. Importantly, the reusable pen device has been designed to simplify therapy administration, making it more user-friendly. As a result, patients can manage their treatment more effectively. Through this collaboration, Zydus aims to significantly broaden access to both the medication and its advanced delivery system.
Expanding Access to Advanced Therapies in India
Overall, the Lupin–Zydus partnership marks a significant step toward improving access to innovative GLP-1 therapies in India. As per the press release, by leveraging complementary strengths, both companies are well-positioned to enhance treatment outcomes and support healthcare providers in managing the growing burden of diabetes and obesity.
